Confocal Laser Endomicroscopy VERification

Brief Summary
The goal of this multi-center randomized clinical trial is to evaluate the added value of needle based confocal laser endomicroscopy (nCLE)-imaging to regular diagnostic bronchoscopic peripheral lung lesion analysis on the diagnostic yield in patients with peripheral pulmonary nodules suspect for malignancy.

The main question\[s\] it aims to answer are:

To determine if the addition of nCLE-imaging to conventional diagnostic bronchoscopic peripheral lung lesion analysis results in an improved diagnostic yield (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis out of the total number of patients that have received the diagnostic bronchoscopic procedure).

Participants will undergo diagnostic bronchoscopy either with or without the addition of nCLE imaging before each TBNA. Based on the feedback of the CLE images on (in)correct placement of the needle, the needle might be repositioned before sampling. Comparison between the diagnostic yield of these groups will be done including subgroup analysis.
Brief Title
Confocal Laser Endomicroscopy VERification
Detailed Description
Rationale: Lung cancer screening and the increasing use of chest-computed tomography (CT) has led to an increase in the number of (incidental) found suspected malignant lung lesions. Since tissue acquisition for pathological analysis is prerequisite for diagnosis and optimal treatment, a drastic increase in the number of patients that need to undergo bronchoscopy is expected.

Over 70% of the suspected lesions develop in the periphery of the lung and are therefore not visible during conventional bronchoscopy. Although several bronchoscopic navigational techniques demonstrated an improved navigation towards the target lesion, the diagnostic yield remains suboptimal due to a substantial near-miss rate. As a result, the need for complementary bronchoscopic guidance that provides real-time feedback on the correct positioning of the biopsy instruments is urgent.

Needle-based Confocal laser endomicroscopy (nCLE) is a novel high-resolution imaging technique that uses an excitation laser light to create 'real-time' microscopic images of tissues. nCLE can be integrated into the biopsy needle, allowing real-time cancer detection at the tip of the biopsy needle during bronchoscopy. The confocal microscope captures autofluorescence of tissues or, combined with intravenously (IV) infused fluorophores (such as fluorescein) allows imaging of individual tumor cells. Recent studies on nCLE-imaging in lung tumors and metastatic lymph nodes have identified and validated nCLE criteria for malignancy (enlarged pleomorphic cells, dark clumps and directional streaming) and airway/lung parenchyma (alveoli, elastin fibres of the conducting airway, bronchial epithelium and still image) and granulomas. A recent study demonstrated that these nCLE-criteria can be used in real-time to fine-tune the needle positioning during ongoing bronchoscopy and thereby potentially improve the diagnostic yield.

This randomized controlled trials aims to evaluate the added value of nCLE-imaging (smart needle) to the conventional used bronchoscopic approach for peripheral lung lesion analysis.

Objective: This multicenter, randomized controlled trial, aims to investigate if nCLE-imaging integrated with conventional bronchoscopy results in a higher diagnostic yield compared to conventional bronchoscopy without nCLE in the diagnosis of peripheral lung nodules.

Study design: Investigator-initiated, international, multi-center randomized controlled trial including university and general hospitals.

Study population: Patients (\>18 years old) with suspected malignant peripheral lung lesions with an indication for bronchoscopic analysis.

Procedure: Bronchoscopy will be performed according to institutional practice, including radial endobronchial ultrasound (r-EBUS) and optionally fluoroscopy, electromagnetic navigation, virtual bronchoscopy and/or ultrathin bronchoscopy. This is followed by transbronchial needle aspiration (TBNA) and (cryo-)biopsies (control arm). In the study arm, nCLE-imaging will be added prior to TBNA tissue acquisition to fine-tune the sampling area. Cytology staining for rapid onsite evaluation (ROSE) and cellblock will be performed according to local practice.

Primary objective:

To determine if the addition of nCLE-imaging to conventional bronchoscopic peripheral lung lesion analysis results in an improved diagnostic yield. (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis out of the total number of patients that have received the diagnostic bronchoscopic procedure).
Central Contacts
Central Contact Role
Contact
Central Contact Phone
+31(0)20 566 2694
Central Contact Email
s.vanheumen@amsterdamumc.nl
Central Contact Role
Contact
Central Contact Email
j.t.annema@amsterdamumc.nl
Completion Date
Completion Date Type
Estimated
Conditions
Lung Cancer
Lung Neoplasm Malignant
Carcinoma, Non-Small-Cell Lung
Neoplasm of Lung
Eligibility Criteria
Inclusion Criteria:

1. ≥18 years of age
2. Suspected malignant peripheral lung lesion with an indication for a bronchoscopic diagnostic work-up as determined by the attending physician or tumor board. Peripheral pulmonary lesions are defined as lesions located beyond the visible segmental bronchi, not detectable by regular flexible bronchoscopy
3. Bronchus sign on pre-procedural CT or estimated confidence for successful navigation to the nodule resulting in a r-EBUS signal
4. Solid part of the lesion must be ≧10 mm
5. Largest dimension of lesion size on CT ≦30 mm (long-axis)
6. Ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

1. Inability or non-willingness to provide informed consent
2. Endobronchial visible malignancy on bronchoscopic inspection
3. Target lesion within reach of the linear EBUS scope
4. Failure to comply with the study protocol
5. Known allergy or risk factors for an allergic reaction to fluorescein
6. Pregnancy or breastfeeding
7. Hemodynamic instability
8. Refractory hypoxemia
9. Therapeutic anticoagulant use that cannot be withheld for an appropriate interval before the procedure
10. Unable to tolerate general anesthesia according to the anesthesiologist
11. Undergoing chemotherapy as several chemotherapies have fluorescent properties at the same wavelength (e.g., doxorubicin)
Inclusion Criteria
Inclusion Criteria:

1. ≥18 years of age
2. Suspected malignant peripheral lung lesion with an indication for a bronchoscopic diagnostic work-up as determined by the attending physician or tumor board. Peripheral pulmonary lesions are defined as lesions located beyond the visible segmental bronchi, not detectable by regular flexible bronchoscopy
3. Bronchus sign on pre-procedural CT or estimated confidence for successful navigation to the nodule resulting in a r-EBUS signal
4. Solid part of the lesion must be ≧10 mm
5. Largest dimension of lesion size on CT ≦30 mm (long-axis)
6. Ability to understand and willingness to sign a written informed consent

Gender
All
Gender Based
false
Keywords
Confocal Microscopy
Bronchoscopy
Confocal laser endomicroscopy
CLE
Fluoroscopy
Healthy Volunteers
No
Last Update Submit Date
Minimum Age
18 Years
NCT Id
NCT06079970
Org Class
Other
Org Full Name
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
Org Study Id
NL83267.018.22
Overall Status
Recruiting
Phases
Not Applicable
Primary Completion Date
Primary Completion Date Type
Estimated
Official Title
Bronchoscopy With and Without Needle-based Confocal Laser Endomicroscopy for Peripheral Lung Nodule Diagnosis: Protocol for a Multicenter Randomized Controlled Trial (CLEVER Trial)
Primary Outcomes
Outcome Description
Diagnostic yield (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis \[either malignant, specific benign or non-specific benign confirmed as benign in follow-up\], relative to the total number of patients that underwent the diagnostic bronchoscopic procedure). If patients with multiple lesions are included, the diagnostic yield will be computed per nodule.
Outcome Measure
Diagnostic yield (intermediate definition)
Outcome Time Frame
After all patients have been included and followed up to 6 months after bronchoscopy (expected total time frame 2 years)
Secondary Outcomes
Outcome Description
Diagnostic sensitivity for malignancy (defined as the proportion of patients in whom the bronchoscopic procedure diagnoses malignancy relative to the total number of patients with a final diagnosis of malignancy as determined by the reference standard).
Outcome Time Frame
After all patients have been included and followed up to 6 months after bronchoscopy (expected total time frame 2 years)
Outcome Measure
Diagnostic sensitivity
Outcome Description
Diagnostic yield according to the strict definition by Vachani et al.(21) (defined as the proportion of patients in whom the bronchoscopic procedure results in a definitive diagnosis \[either malignant or specific benign diagnosis\], relative to the total number of patients that underwent the diagnostic bronchoscopic procedure).
Outcome Time Frame
After all patients have been included (expected total time frame 2 years)
Outcome Measure
Diagnostic yield (strict definition)
Outcome Description
Procedure duration (from bronchoscope insertion until removal).
Outcome Time Frame
During procedure (bronchoscopy)
Outcome Measure
Procedure duration
Outcome Description
Percentage of patients in which the needle was fine-tuned (defined as moving the needle within the same distal airway) or repositioned (defined as the selection of a different distal airway for tissue sampling) based on nCLE feedback (defined as the number of patients the needle was fine-tuned/repositioned divided by the total number of patients in which nCLE imaging was used).
Outcome Time Frame
During procedure (bronchoscopy)
Outcome Measure
Proportion needle repositionings and fine-tuning
Outcome Description
Fluoroscopy radiation time and dose.
Outcome Time Frame
During procedure (bronchoscopy)
Outcome Measure
Fluoroscopy time/dose
Outcome Description
Diagnostic yield of ROSE (defined as the proportion of patients in whom ROSE resulted in a classifying diagnosis \[malignant or specific benign diagnosis\], relative to the total number of patients).
Outcome Time Frame
After all patients have been included and followed up to 6 months after bronchoscopy (expected total time frame 2 years)
Outcome Measure
Yield ROSE
Outcome Description
Proportion of patients in which ROSE provided tool-in-lesion confirmation, meaning that the acquired tissue shows signs of a malignant or non-malignant diagnosis and was not related to airway/lung parenchyma sampling such as bronchus epithelium/blood contamination, and tissue not suitable for a specific diagnosis such as atypical cells.
Outcome Time Frame
During procedure (bronchoscopy)
Outcome Measure
ROSE tool-in-lesion
Outcome Description
Complication rate (defined as any complication or complication categories occurring during or directly after the bronchoscopic procedure or any procedure-related complication within one week after the procedure).
Outcome Time Frame
Up to 1 week after bronchoscopy
Outcome Measure
Complication rate
Outcome Description
Requirement of additional diagnostic procedures (CT-guided transthoracic biopsies, surgical diagnostics and/or additional bronchoscopy) during the 6-month follow-up period.
Outcome Time Frame
Up to 6 months after index bronchoscopy
Outcome Measure
Additional diagnostics needed
Outcome Description
To assess the diagnostic yield (primary outcome) for two subgroups (≤20 mm vs \>20 mm)
Outcome Time Frame
After all patients have been included and followed up to 6 months after bronchoscopy (expected total time frame 2 years)
Outcome Measure
Diagnostic yield subgroup analysis (stratified by lesion size in mm)
Outcome Description
To assess the diagnostic yield (primary outcome) for three subgroups (eccentric vs concentric vs absent)
Outcome Time Frame
After all patients have been included and followed up to 6 months after bronchoscopy (expected total time frame 2 years)
Outcome Measure
Diagnostic yield subgroup analysis (stratified rEBUS visibility)
Outcome Description
To assess the diagnostic yield (primary outcome) for three subgroups (upper lobe (without lingual) vs middle lobe/lingual vs lower lobe)
Outcome Time Frame
After all patients have been included and followed up to 6 months after bronchoscopy (expected total time frame 2 years)
Outcome Measure
Diagnostic yield subgroup analysis (stratified by location in the lung)
Outcome Description
To assess the diagnostic yield (primary outcome) for three subgroups (Brock score \<10%, 10 - 35%, 36-70% and \>70%)
Outcome Time Frame
After all patients have been included and followed up to 6 months after bronchoscopy (expected total time frame 2 years)
Outcome Measure
Diagnostic yield subgroup analysis (stratified by Brock score)
Start Date
Start Date Type
Actual
Status Verified Date
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Ali Sadoughi
Investigator Email
asadough@montefiore.org
Investigator Phone
718-920-5965
Investigator Department
Medicine
Investigator Division
Pulmonary Medicine
Investigator Sponsor Organization
Montefiore
Study Department
Medicine
Study Division
Please Specify
Categories Mesh Debug
Lung & Chest Cancers --- LUNG NEOPLASMS
Lung & Chest Cancers --- CARCINOMA, NON-SMALL-CELL LUNG
Lung & Chest Cancers --- RESPIRATORY TRACT NEOPLASMS
Lung & Chest Cancers --- THORACIC NEOPLASMS
Cancer --- NEOPLASMS BY SITE
Cancer --- NEOPLASMS
Lung & Chest Cancers --- LUNG DISEASES
COVID-19 --- LUNG DISEASES
Lung --- LUNG DISEASES
Asthma and Other Respiratory Diseases --- RESPIRATORY TRACT DISEASES
Lung & Chest Cancers --- RESPIRATORY TRACT DISEASES
COVID-19 --- RESPIRATORY TRACT DISEASES
Lung --- RESPIRATORY TRACT DISEASES
Lung & Chest Cancers --- CARCINOMA, BRONCHOGENIC
Lung & Chest Cancers --- BRONCHIAL NEOPLASMS
MeSH Terms
LUNG NEOPLASMS
CARCINOMA, NON-SMALL-CELL LUNG
RESPIRATORY TRACT NEOPLASMS
THORACIC NEOPLASMS
NEOPLASMS BY SITE
NEOPLASMS
LUNG DISEASES
RESPIRATORY TRACT DISEASES
CARCINOMA, BRONCHOGENIC
BRONCHIAL NEOPLASMS